Troglitazone: The lesson that nobody learned?

Diabetologia

Volumn 49, Issue 1, 2006, Pages 1-6

  Gale, Edwin A M ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; INSULIN; LIVER ENZYME; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TROGLITAZONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG APPROVAL; DRUG CHOICE; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG SAFETY; EDITORIAL; FATALITY; FOOD AND DRUG ADMINISTRATION; GLUCOSE TOLERANCE; HEART FAILURE; HUMAN; JAUNDICE; LIVER BIOPSY; LIVER FAILURE; LIVER FUNCTION TEST; LIVER GRAFT; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT MONITORING; PEROXISOME; PRIORITY JOURNAL;

CHROMANS; DIABETES MELLITUS, TYPE 2; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 31444449995     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-0074-6     Document Type: Editorial

References (25)

1. Anonymous (1999) The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623-634
2. Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 346:393-403
3. Willman D (2000) The rise and fall of the killer drug Rezulin. Los Angeles Times, 4 June. Reprint available from http://www.lef.org/magazine/ mag2000/sep2000_report_rezulin.html, last accessed in October 2005
4. National Institute of Diabetes and Digestive and Kidney Diseases (1998) NIDDK discontinues troglitazone arm of "Diabetes Prevention Program" clinical trial. NIDDK, Bethesda. Available from http://www.niddk.nih.gov/ welcome/releases/6_4_98.htm, last accessed in October 2005
5. Willman D (1998) Drug maker hires NIH researcher. Los Angeles Times, 7 December. Available from http://www.house.gov/waxman/news_files/ news_letters_rezulin_press_NIH_sci_denies_12_7_98.htm, last accessed in October 2005
6. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New Engl J Med 331:1188-1193
7. Olefsky J, Antonucci T, Lockwood D, Norris R. Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus. US Patent 5,478,852, filed 23 August 1994. Available from http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d= PALL&p=1&u=/netahtml/srchnum.htm&r=l&f=G&l=50&s1=5,478, 852.WKU&OS=PN/5,478,852&RS=PN/5,478,852, last accessed in October 2005
8. Olefsky J. Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus. US Patent 5,708,012, filed 28 April 1995. Available from http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2= HITOFF&d=PALL&p=1&u=/netahtml/srchnum.htm&r=l&f=G&l= 50&s1=5708012.WKU.&OS=PN/5708012&RS=PN/5708012, last accessed in October 2005
9. Varmus H (1998) Letter to Henry A. Waxman, House of Representatives, 29 December. Available from http://www.henrywaxman.house.gov/news_files/ news_letters_rezluin_2_19_99_NIH_response.htm, last accessed in October 2005
10. US Department of Health and Human Services/Food and Drug Administration (1997) FDA approves rezulin for diabetes patients poorly controlled on insulin therapy. FDA Talk Paper, 30 January. Available from http://www.fda.gov/bbs/ topics/ANSWERS/ANS00783.html, last accessed in October 2005
11. Anonymous (1995) Warner-Lambert Company. Corporate Crime Reporter 46, 4 December. Available from http://www.corporatecrimereporter.com/top100. html#Annotated, last accessed in October 2005
12. US Department of Health and Human Services/Food and Drug Administration (1996) Endocrinologic and Metabolic Drugs Advisory Committee. Troglitazone for diabetes mellitus. Meeting no. 65. USDHHS/FDA, Bethesda, 11 December. Available from http://www.fda.gov/ohrms/dockets/ac/96/transcpt/3255t2a.pdf; http://www.fda.gov/ohrms/dockets/ac/nscpt/3255t2c.pdf; http://www.fda.gov/ohrms/ dockets/ac/96/transcpt/3255t2d.pdf; all last accessed in October 2005
13. King KF (2000) Letter to Jane E. Henney, Food and Drug Administration. Parke-Davis, Morris Plains, 20 March. Available from http://web.archive.org/web/ 20001015184650/www.warner-lambert.com/Rezulin/henney.html, last accessed in October 2005
14. IMS Health (1998) Business Watch: 1997 at a glance. IMS Health, Fairfield
15. Anonymous (1997) Troglitazone (Romozin) withdrawn. Current Problems in Pharmacovigilance 23:13-16. Available from http://www.mhra.gov.uk/home/groups/ pl-p/documents/publication/con007478.htm#Troglitazone, last accessed in October 2005
16. Wolfe SM (2000) Letter to the FDA requesting a criminal investigation of Warner Lambert/Parke Davis for what appears to be illegally delaying the submission of data known to the company before troglitazone was marketed. HRG Publication #1515. Public Citizen's Health Research Group, Washington, 14 March. Available from http://www.citizen.org/publications/print_release.cfm?ID=6716, last accessed in October 2005
17. Graham D, Green L (2000) Memorandum. Final report: Liver failure risk with troglitazone (Rezulin) NDA: 20-720. USDHHS, FDA, Center for Drug Evaluation and Research, Bethesda. 19 December
18. Sigmund WR 2nd (1997) Dear Healthcare Professional. Parke-Davis, Morris Plains, 1 December. Available from http://www.fda.gov/medwatch/SAFETY/1997/ rezul3.htm, last accessed in October 2005
19. Watkins PB, Whitcomb RW (1998) Hepatic dysfunction associated with troglitazone. New Engl J Med 338:916-917
20. Wolfe SM, Sasich L (1998) Petition to the Food and Drug Administration to ban troglitazone/Rezulin due to its causing several cases of liver failure. HRG Publication #1449. Public Citizen's Health Research Group, Washington, 27 July. Available from http://www.citizen.org/publications/release.cfm?ID=6647, last accessed in October 2005
21. Wolfe SM (1999) Statement before the Food and Drug Administration Endocrine and Metabolic Drugs Advisory Committee meeting advising them to withdraw troglitazone from the U.S. Market. HRG Publication #1476. Public Citizen's Health Research Group, Washington, 26 March. Available from http://www.citizen.org/publications/release.cfm?ID=6674, last accessed in October 2005
22. Horwitz KB, Mallin SR (1999) Letter to Endocrinologic & Metabolic Drug Advisory Committee on Rezulin. Re: Rezulin (troglitazone). Endocrine Society, Bethesda, 24 March. Available from http://www.endo-society.org/ publicpolicy/legislative/letters/fdaletter.cfm, last accessed in October 2005
23. Gale EAM (2001) Lessons from the glitazones: a story of drug development. Lancet 357:1870-1875
24. DeRenzo EG (2005) Conflict-of-interest policy at the National Institutes of Health: the pendulum swings wildly. Kennedy Inst Ethics J 15:199-210
25. Gale EAM (2003) Between two cultures: the expert clinician and the pharmaceutical industry. Clin Med 3:538-541